Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Net Income (2019 - 2025)

Historic Net Income for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to -$26.7 million.

  • aTYR PHARMA's Net Income fell 4741.22% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.7 million, marking a year-over-year decrease of 1557.32%. This contributed to the annual value of -$67.9 million for FY2024, which is 2366.21% down from last year.
  • Per aTYR PHARMA's latest filing, its Net Income stood at -$26.7 million for Q3 2025, which was down 4741.22% from -$20.3 million recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's Net Income peaked at -$8.0 million during Q4 2022, and registered a low of -$26.7 million during Q3 2025.
  • In the last 4 years, aTYR PHARMA's Net Income had a median value of -$15.8 million in 2024 and averaged -$15.7 million.
  • The largest annual percentage gain for aTYR PHARMA's Net Income in the last 5 years was 650.01% (2023), contrasted with its biggest fall of 10074.21% (2023).
  • Over the past 4 years, aTYR PHARMA's Net Income (Quarter) stood at -$8.0 million in 2022, then crashed by 100.74% to -$16.0 million in 2023, then grew by 0.87% to -$15.8 million in 2024, then plummeted by 69.06% to -$26.7 million in 2025.
  • Its Net Income stands at -$26.7 million for Q3 2025, versus -$20.3 million for Q2 2025 and -$15.8 million for Q1 2025.